Market research
V7B1.F Assembly Biosciences, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 52M
- P/E ratio
- Not available
- Analyst target
- 9.71
- Dividend yield
- 0.0%
- Beta
- 0.62
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0453961080
- Market cap
- 52M
- P/E ratio
- Not available
- Analyst target
- 9.71
- Dividend yield
- 0.0%
- Beta
- 0.62
About
About Assembly Biosciences, Inc
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. It also has a clinical collaboration agreement with Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the V7B1.F discussion.
5 years, 5 months ago
Assembly Biosciences, Inc is currently in a long term downtrend where the price is trading 45.5% below its 200 day moving average.
From a valuation standpoint, the stock is 83.5% cheaper than other stocks from the Other sector with a price to sales ratio of 2.1.
Assembly Biosciences, Inc's total revenue sank by 78.2% to $1M since the same quarter in the previous year.
Its net income has dropped by 45.5% to $-39M since the same quarter in the previous year.
Finally, its free cash flow fell by 31.5% to $-27M since the same quarter in the previous year.
Based on the above factors, Assembly Biosciences, Inc gets an overall score of 1/5.